{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:39:18Z","timestamp":1780450758697,"version":"3.54.1"},"reference-count":173,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Psychiatric disorders are a major cause of illness in the world. Unfortunately, many patients are resistant to treatment and present serious complications. Schizophrenia is refractory to treatment in about one-third of patients. Antidepressants are effective in about half of patients. Suicidal ideation is an increasing issue in patients with mixed features in bipolar disorder (BD). Therefore, there is a need to develop and test new drugs or new indications of available medications for the treatment of psychiatric disorders through evidence-based investigations. This narrative review aims to present the molecules approved by the main drug agencies, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), from 2018 to date, along with new indications and new formulations of existing medications. We searched PubMed for new drugs approved for schizophrenia, BD, major depressive disorder (MDD), anxiety disorders, and obsessive-compulsive disorder (OCD). We evaluated their clinical benefits, safety, and tolerability profiles. Finally, we considered studies on the main molecules that have shown initial evidence of efficacy and are in the process of obtaining approval. Our search suggested that a new antipsychotic, lumateperone, and two drug combinations, olanzapine\/samidorphan (OLZ\/SAM) and xanomeline\/trospium (KarXT), were approved for schizophrenia. In addition, some new methods of administration\u2014monthly risperidone administration, subcutaneous risperidone administration, and transdermal asenapine administration\u2014obtained approval from the main drug agencies. Lumateperone and OLZ\/SAM were also approved in BD. Esketamine, a compound that modulates glutamatergic transmission, was approved to treat treatment-resistant depression and acute suicidal ideation. The dextromethorphan\/bupropion combination was approved for MDD. Two new agents, brexanolone and zuranolone, were approved for treatment of postpartum depression. On the other hand, no new drugs received approval for anxiety disorders or OCD. In summary, some new psychotropic medications have been developed, in particular with the aim to improve the symptoms of resistant patients and to decrease the incidence of adverse effects. It is necessary to continue testing the effectiveness of new compounds in methodologically rigorous studies.<\/jats:p>","DOI":"10.3390\/ph18050665","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:35:13Z","timestamp":1746185713000},"page":"665","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-3467","authenticated-orcid":false,"given":"Paola","family":"Bozzatello","sequence":"first","affiliation":[{"name":"Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0399-102X","authenticated-orcid":false,"given":"Roberta","family":"Novelli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Schisano","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9363-2506","authenticated-orcid":false,"given":"Claudio","family":"Brasso","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-3559","authenticated-orcid":false,"given":"Paola","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-8000","authenticated-orcid":false,"given":"Silvio","family":"Bellino","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"GBD 2019 Mental Disorders Collaborators (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry, 9, 137\u2013150.","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pneurobio.2017.03.002","article-title":"Ethical challenges in developing drugs for psychiatric disorders","volume":"152","author":"Carrier","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: State of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1176\/appi.ps.201400044","article-title":"The diminished pipeline for medications to treat mental health and substance use disorders","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"ref_5","first-page":"e56561","article-title":"A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018\u20132022)","volume":"16","author":"Giliberto","year":"2024","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2020.12.006","article-title":"Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia","volume":"228","author":"Correll","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/YIC.0000000000000371","article-title":"Safety and tolerability of lumateperone for the treatment of schizophrenia: A pooled analysis of late-phase placebo- and active-controlled clinical trials","volume":"36","author":"Kane","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/JCP.0000000000001076","article-title":"Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program","volume":"39","author":"Andorn","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2147\/PPA.S202173","article-title":"Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study","volume":"13","author":"Dhanda","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","article-title":"Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: A randomised clinical trial in the USA and Bulgaria","volume":"10","author":"Kane","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40263-024-01102-2","article-title":"A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial","volume":"38","author":"Kane","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2021.11.030","article-title":"Long-term efficacy and safety of once-monthly Risperidone ISM\u00ae in the treatment of schizophrenia: Results from a 12-month open-label extension study","volume":"239","author":"Filts","year":"2022","journal-title":"Schizophr. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.4088\/JCP.20m13602","article-title":"Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients with Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study","volume":"82","author":"Citrome","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.schres.2017.10.014","article-title":"A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers","volume":"195","author":"Silverman","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of Olanzapine-Induced Weight Gain with Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients with Schizophrenia","volume":"176","author":"Martin","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpdd.601","article-title":"Bioequivalence of Olanzapine Given in Combination with Samidorphan as a Bilayer Tablet (ALKS 3831) Compared with Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study","volume":"8","author":"Sun","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.2147\/DDDT.S205000","article-title":"Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet","volume":"13","author":"Sun","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.4088\/JCP.19m12769","article-title":"Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients with an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study","volume":"81","author":"Potkin","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of Olanzapine Combined with Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study","volume":"177","author":"Correll","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S1092852920001376","article-title":"Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: Results from a 1-year open-label extension study","volume":"26","author":"Yagoda","year":"2021","journal-title":"CNS Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sun, L., Yagoda, S., Xue, H., Brown, R., Nangia, N., McDonnell, D., Rege, B., Moltke, L., and Darpo, B. (2020). Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT\/QTc study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 100.","DOI":"10.1016\/j.pnpbp.2020.109881"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2021.04.009","article-title":"A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension","volume":"232","author":"Kahn","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bdi.13310","article-title":"Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial","volume":"25","author":"Suppes","year":"2023","journal-title":"Bipolar Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22m14674","DOI":"10.4088\/JCP.22m14674","article-title":"Olanzapine\/Samidorphan in Young Adults with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study","volume":"84","author":"Kahn","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: Interim results of the SUSTAIN-3 study","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial","volume":"179","author":"Tabuteau","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"41226","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients with Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI)","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: A randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Colquhoun","year":"2018","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the Treatment of Postpartum Depression","volume":"180","author":"Deligiannidis","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"ref_38","first-page":"26","article-title":"Substance abuse in schizophrenia: A review","volume":"59","author":"Buckley","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s12325-017-0507-x","article-title":"Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly","volume":"34","author":"Biagi","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_40","first-page":"27","article-title":"Treatment strategies to prevent relapse and encourage remission","volume":"68","author":"Kane","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Priede","year":"2012","journal-title":"Schizophr. Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Orzelska-G\u00f3rka, J., Mikulska, J., Wiszniewska, A., and Bia\u0142a, G. (2022). New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810624"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"St\u0119pnicki, P., Kondej, M., and Kaczor, A.A. (2018). Current Concepts and Treatments of Schizophrenia. Molecules, 23.","DOI":"10.3390\/molecules23082087"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.clinthera.2017.08.008","article-title":"Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics","volume":"39","author":"Pilon","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1038\/mp.2017.156","article-title":"Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia","volume":"23","author":"Greene","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/0004867419837358","article-title":"Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome","volume":"53","author":"Olagunju","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YCO.0000000000000685","article-title":"Agitation in schizophrenia: Origins and evidence-based treatment","volume":"34","author":"Citrome","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr. Bull."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11920-021-01298-w","article-title":"New Antipsychotic Medications in the Last Decade","volume":"23","author":"Pahwa","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14656566.2020.1717466","article-title":"Pharmacological strategies for the management of comorbid depression and schizophrenia","volume":"21","author":"Ceskova","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","article-title":"Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study","volume":"36","author":"Nasser","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.schres.2016.03.020","article-title":"Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study","volume":"174","author":"Isitt","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2147\/NDT.S459104","article-title":"TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia","volume":"20","author":"Citrome","year":"2024","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41537-020-00127-y","article-title":"Efficacy and safety of once-monthly Risperidone ISM\u00ae in schizophrenic patients with an acute exacerbation","volume":"6","author":"Correll","year":"2020","journal-title":"npj Schizophr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2147\/PPA.S235104","article-title":"Transdermal Asenapine in Schizophrenia: A Systematic Review","volume":"14","author":"Carrithers","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.24869\/psyd.2019.157","article-title":"Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders","volume":"31","author":"Reyad","year":"2019","journal-title":"Psychiatr. Danub."},{"key":"ref_61","first-page":"803","article-title":"Asenapine review, part II: Clinical efficacy, safety and tolerability","volume":"13","author":"Citrome","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/JCP.0000000000001383","article-title":"Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)","volume":"41","author":"Suzuki","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Srisurapanont, M., Suttajit, S., Likhitsathian, S., Maneeton, B., and Maneeton, N. (2021). A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine\/samidorphan and olanzapine. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-87285-w"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia","volume":"174","author":"Davidson","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"pyae061","DOI":"10.1093\/ijnp\/pyae061","article-title":"Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients with Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial","volume":"28","author":"Anand","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","article-title":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders\u2014A comprehensive systematic review and meta-analysis","volume":"90","author":"Jeppesen","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"105325","DOI":"10.1016\/j.phrs.2020.105325","article-title":"Inflammation in Bipolar Disorder (BD): Identification of new therapeutic targets","volume":"163","author":"Pereira","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wilkowska, A., and Cuba\u0142a, W.J. (2023). Short-term ketamine use in bipolar depression: A review of the evidence for short-term treatment management. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1322752"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.5498\/wjp.v14.i10.1573","article-title":"Association between 5-HTR1A gene C-1019G polymorphism and antidepressant response in patients with major depressive disorder: A meta-analysis","volume":"14","author":"Wu","year":"2024","journal-title":"World J. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40265-023-01872-x","article-title":"New Pharmacologic Approaches to the Treatment of Bipolar Depression","volume":"83","author":"Keramatian","year":"2023","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamapsychiatry.2019.0779","article-title":"Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults with Bipolar I\/II Depression: A Randomized Clinical Trial","volume":"76","author":"McIntyre","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100383","DOI":"10.1016\/j.bbih.2021.100383","article-title":"Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency","volume":"18","author":"Nikkheslat","year":"2021","journal-title":"Brain Behav. Immun. Health"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","article-title":"Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments","volume":"22","author":"Kadriu","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/NDT.S325000","article-title":"Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study","volume":"17","author":"Wilkowska","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13651501.2017.1297834","article-title":"Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression","volume":"21","author":"Rybakowski","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.7717\/peerj.10208","article-title":"Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: A preliminary study","volume":"8","author":"Zheng","year":"2020","journal-title":"PeerJ"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e01674","DOI":"10.1002\/brb3.1674","article-title":"Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression\u2014An open-label three-week pilot study","volume":"10","author":"Zhuo","year":"2020","journal-title":"Brain Behav."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20451253231202723","DOI":"10.1177\/20451253231202723","article-title":"Ketamine for bipolar depression: An updated systematic review","volume":"13","author":"Fancy","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine Nasal Spray Plus Oral Antidepressant in Patients with Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"57118","DOI":"10.4088\/JCP.24m15376","article-title":"Efficacy and Safety of Ketamine\/Esketamine in Bipolar Depression in a Clinical Setting","volume":"85","author":"Santucci","year":"2024","journal-title":"J. Clin. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40345-023-00308-5","article-title":"NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: A randomized prospective phase 2 trial","volume":"11","author":"Nierenberg","year":"2023","journal-title":"Int. J. Bipolar Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2018.02.004","article-title":"Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment","volume":"102","author":"Edberg","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2215-0366(20)30138-3","article-title":"Minocycline and celecoxib as adjunctive treatments for bipolar depression: A multicentre, factorial design randomised controlled trial","volume":"7","author":"Husain","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40263-024-01114-y","article-title":"Glutamatergic Modulators for Major Depression from Theory to Clinical Use","volume":"38","author":"McIntyre","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41398-025-03255-0","article-title":"Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: A systematic review","volume":"15","author":"Sajid","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jad.2023.01.005","article-title":"Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial","volume":"325","author":"Ahmed","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e067194","DOI":"10.1136\/bmj-2021-067194","article-title":"Ketamine for the acute treatment of severe suicidal ideation: Double blind, randomised placebo controlled trial","volume":"376","author":"Abbar","year":"2022","journal-title":"BMJ"},{"key":"ref_90","first-page":"18","article-title":"Efficacy and dose-response relationships of antidepressants in the acute treatment of major depressive disorders: A systematic review and network meta-analysis","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","article-title":"A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression and Prominent Suicidal Ideation","volume":"26","author":"Su","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"609","DOI":"10.9758\/cpn.23.1081","article-title":"Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder","volume":"21","author":"McCarthy","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_93","first-page":"e32745","article-title":"A Comprehensive Review on Postpartum Depression","volume":"14","author":"Suryawanshi","year":"2022","journal-title":"Cureus"},{"key":"ref_94","first-page":"115","article-title":"Brexanolone to Treat Postpartum Depression in Adult Women","volume":"51","author":"Cornett","year":"2021","journal-title":"Psychopharmacol. Bull."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40262-022-01155-w","article-title":"Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy Volunteers Receiving Brexanolone Injection, with Population Pharmacokinetic Modeling of Potential Relative Infant Dose","volume":"61","author":"Wald","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ahmad, A., Awan, A.R., Nadeem, N., Javed, A.S., Farooqi, M., Daniyal, M., and Mumtaz, H. (2024). Zuranolone for treatment of major depressive disorder: A systematic review and meta-analysis. Front. Neurosci., 18.","DOI":"10.3389\/fnins.2024.1361692"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clinthera.2024.04.001","article-title":"Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression","volume":"46","author":"Hitt","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Melani, A., Bonaso, M., Biso, L., Zucchini, B., Conversano, C., and Scarselli, M. (2025). Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications. Pharmaceuticals, 18.","DOI":"10.3390\/ph18010130"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40263-021-00877-y","article-title":"Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression","volume":"36","author":"Ling","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Caldiroli, A., Colzani, L., Capuzzi, E., Quitadamo, C., La Tegola, D., Surace, T., Russo, S., Capetti, M., Leo, S., and Tringari, A. (2023). Clinical Markers of Panic and Generalized Anxiety Disorder: Overlapping Symptoms, Different Course and Outcome. J. Pers. Med., 13.","DOI":"10.3390\/jpm13030491"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Garakani, A., Murrough, J.W., Freire, R.C., Thom, R.P., Larkin, K., Buono, F.D., and Iosifescu, D. (2020). Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.595584"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50 years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic Acid Diethylamide-Assisted Therapy in Patients with Anxiety with and without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2024.99","article-title":"LSD-assisted therapy in patients with anxiety: Open-label prospective 12-month follow-up","volume":"225","author":"Holze","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"van der Kolk, B.A., Wang, J.B., Yehuda, R., Bedrosian, L., Coker, A.R., Harrison, C., Mithoefer, M., Yazar-Klosinki, B., Emerson, A., and Doblin, R. (2024). Effects of MDMA-assisted therapy for PTSD on self-experience. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0295926"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1176\/appi.focus.23021011","article-title":"MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study","volume":"21","author":"Mitchell","year":"2023","journal-title":"Focus"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2006.03.084","article-title":"Effects of D-cycloserine on extinction: Translation from preclinical to clinical work","volume":"60","author":"Davis","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"ref_110","first-page":"CD007803","article-title":"Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders","volume":"2015","author":"Ori","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","article-title":"D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data","volume":"74","author":"Monzani","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.janxdis.2017.11.004","article-title":"Does d-cycloserine facilitate the effects of homework compliance on social anxiety symptom reduction?","volume":"53","author":"Roque","year":"2018","journal-title":"J. Anxiety Disord."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"103607","DOI":"10.1016\/j.brat.2020.103607","article-title":"Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: A randomized placebo-controlled trial","volume":"129","author":"Reinecke","year":"2020","journal-title":"Behav. Res. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10578-018-0837-1","article-title":"N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents","volume":"50","author":"Leyfer","year":"2019","journal-title":"Child Psychiatry Hum. Dev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpsychires.2024.10.018","article-title":"The potential effect of d-cycloserine on the development of anxiety during exposure sessions in patients with agoraphobia","volume":"181","author":"Pyrkosch","year":"2025","journal-title":"J. Psychiatr. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jpsychires.2018.08.016","article-title":"Learn to forget: Does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia?","volume":"105","author":"Pyrkosch","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/jpm.2012.0617","article-title":"Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial","volume":"16","author":"Irwin","year":"2013","journal-title":"J. Palliat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","article-title":"Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study","volume":"34","author":"Glue","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1176\/appi.focus.23021014","article-title":"A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder","volume":"21","author":"Feder","year":"2023","journal-title":"Focus"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41386-022-01339-9","article-title":"Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial","volume":"47","author":"Abdallah","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"104073","DOI":"10.1016\/j.ajp.2024.104073","article-title":"Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg\/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial","volume":"97","author":"Gundugurti","year":"2024","journal-title":"Asian J. Psychiatr."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Masataka, N. (2019). Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers with Social Anxiety Disorders. Front. Psychol., 10.","DOI":"10.3389\/fpsyg.2019.02466"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euroneuro.2022.04.003","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial","volume":"59","author":"Kwee","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1590\/1516-4446-2021-2317","article-title":"The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event","volume":"44","author":"Bolsoni","year":"2022","journal-title":"Braz. J. Psychiatry"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"42111","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial","volume":"83","author":"Berger","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.pnpbp.2010.02.028","article-title":"Neuroimaging in social anxiety disorder: A systematic review of the literature","volume":"34","author":"Hallak","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/da.22664","article-title":"Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?","volume":"34","author":"Turna","year":"2017","journal-title":"Depress. Anxiety"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/16506073.2017.1321683","article-title":"App-guided exposure and response prevention for obsessive compulsive disorder: An open pilot trial","volume":"46","author":"Boisseau","year":"2017","journal-title":"Cogn. Behav. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.euroneuro.2016.02.006","article-title":"The cost and impact of compulsivity: A research perspective","volume":"26","author":"Hollander","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"19r13085","DOI":"10.4088\/JCP.19r13085","article-title":"Women Are at Greater Risk of OCD Than Men: A Meta-Analytic Review of OCD Prevalence Worldwide","volume":"81","author":"Fawcett","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.focus.19402","article-title":"Pharmacological and Psychotherapeutic Interventions for Management of Obsessive-Compulsive Disorder in Adults: A Systematic Review and Network Meta-Analysis","volume":"19","author":"Skapinakis","year":"2021","journal-title":"Focus"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/7854_2020_204","article-title":"Pharmacotherapeutic Strategies and New Targets in OCD","volume":"49","author":"Pittenger","year":"2021","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.4088\/JCP.14r09758","article-title":"Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: A meta-analysis","volume":"77","author":"Issari","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_138","first-page":"CD001765","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","volume":"2008","author":"Soomro","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/B978-0-444-64076-5.00049-1","article-title":"Genetic susceptibility in obsessive-compulsive disorder","volume":"148","author":"Fernandez","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.biopsych.2019.09.029","article-title":"De Novo Damaging DNA Coding Mutations Are Associated with Obsessive-Compulsive Disorder and Overlap with Tourette\u2019s Disorder and Autism","volume":"87","author":"Cappi","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.b.32137","article-title":"Meta-analysis of association between obsessive-compulsive disorder and the 3\u2032 region of neuronal glutamate transporter gene SLC1A1","volume":"162","author":"Stewart","year":"2013","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/mp.2014.43","article-title":"Genome-wide association study in obsessive-compulsive disorder: Results from the OCGAS","volume":"20","author":"Mattheisen","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jad.2017.02.017","article-title":"Disgust proneness predicts obsessive-compulsive disorder symptom severity in a clinical sample of youth: Distinctions from negative affect","volume":"213","author":"Olatunji","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11634510-000000000-00000","article-title":"Elucidating the mechanism of action of pregabalin: \u03b1(2)\u03b4 as a therapeutic target in anxiety","volume":"26","author":"Prieto","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1017\/S1092852919001500","article-title":"Pregabalin augmentation for resistant obsessive-compulsive disorder: A double-blind placebo-controlled clinical trial","volume":"25","author":"Mowla","year":"2020","journal-title":"CNS Spectr."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0043-120268","article-title":"Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial","volume":"51","author":"Modarresi","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Askari, S., Mokhtari, S., Shariat, S.V., Shariati, B., Yarahmadi, M., and Shalbafan, M. (2022). Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry, 22.","DOI":"10.1186\/s12888-021-03642-z"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"112602","DOI":"10.1016\/j.psychres.2019.112602","article-title":"A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder","volume":"282","author":"Modarresi","year":"2019","journal-title":"Psychiatry Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/JCP.0000000000000651","article-title":"Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"37","author":"Sahraian","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.4088\/JCP.19f13163","article-title":"Augmentation with Memantine in Obsessive-Compulsive Disorder","volume":"80","author":"Andrade","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/1871524913666140109113341","article-title":"Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders","volume":"13","author":"Jatana","year":"2013","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson\u2019s disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/YIC.0000000000000368","article-title":"Tolcapone in obsessive-compulsive disorder: A randomized double-blind placebo-controlled crossover trial","volume":"36","author":"Grant","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2165\/11530240-000000000-00000","article-title":"Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: A preliminary, single-blind, prospective study","volume":"23","author":"Pallanti","year":"2009","journal-title":"CNS Drugs"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41386-018-0174-x","article-title":"High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions","volume":"44","author":"Stern","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/YIC.0000000000000267","article-title":"Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: A randomized double-blind placebo-controlled study","volume":"34","author":"Sharafkhah","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"152352","DOI":"10.1016\/j.comppsych.2022.152352","article-title":"Treatment-resistant OCD: Pharmacotherapies in adults","volume":"120","author":"Grassi","year":"2023","journal-title":"Compr. Psychiatry"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","article-title":"N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study","volume":"29","author":"Sarris","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Sarris, J., Byrne, G., Castle, D., Bousman, C., Oliver, G., Cribb, L., Blair-West, S., Brakoulias, V., Camfield, D., and Ee, C. (2022). N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry, 117.","DOI":"10.1016\/j.pnpbp.2022.110550"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/cap.2019.0041","article-title":"N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study","volume":"30","author":"Li","year":"2020","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1748-6653.2011.02021.x","article-title":"Comparative neuropsychology of adult obsessive-compulsive disorder and attention deficit\/hyperactivity disorder: Implications for a novel executive overload model of OCD","volume":"6","author":"Abramovitch","year":"2012","journal-title":"J. Neuropsychol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"102316","DOI":"10.1016\/j.janxdis.2020.102316","article-title":"But first, coffee: The roles of arousal and inhibition in the resistance of compulsive cleansing in individuals with high contamination fears","volume":"76","author":"Naftalovich","year":"2020","journal-title":"J. Anxiety Disord."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.euroneuro.2018.12.010","article-title":"Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study","volume":"29","author":"Zheng","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/da.23032","article-title":"Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study","volume":"37","author":"Kayser","year":"2020","journal-title":"Depress. Anxiety"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/can.2018.0050","article-title":"Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey","volume":"4","author":"Milosev","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Buot, A., Pallares, C., Oganesyan, A., Daur\u00e9, C., Bonnelle, V., Burgui\u00e8re, E., Alves Dos Santos, J.F., N\u2019Diaye, K., Ljuslin, M., and Smit, P. (2023). Improvement in OCD symptoms associated with serotoninergic psychedelics: A retrospective online survey. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-39812-0"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jad.2020.09.124","article-title":"Acute Effects of Cannabis on Symptoms of Obsessive-Compulsive Disorder","volume":"279","author":"Mauzay","year":"2021","journal-title":"J. Affect Disord."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/7854_2021_279","article-title":"Psilocybin for the Treatment of Obsessive-Compulsive Disorders","volume":"56","author":"Ehrmann","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e12135","DOI":"10.1016\/j.heliyon.2022.e12135","article-title":"Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report","volume":"8","author":"Kelmendi","year":"2022","journal-title":"Heliyon"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","article-title":"Expectancy in placebo-controlled trials of psychedelics: If so, so what?","volume":"239","author":"Butler","year":"2022","journal-title":"Psychopharmacology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/665\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:25:18Z","timestamp":1760030718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":173,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ph18050665"],"URL":"https:\/\/doi.org\/10.3390\/ph18050665","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}